Canada - English - Health Canada

novartis pharmaceuticals canada inc - valsartan (sacubitril valsartan sodium hydrate complex); sacubitril (sacubitril valsartan sodium hydrate complex) - tablet - 51mg; 49mg - valsartan (sacubitril valsartan sodium hydrate complex) 51mg; sacubitril (sacubitril valsartan sodium hydrate complex) 49mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

novartis pharmaceuticals canada inc - valsartan (sacubitril valsartan sodium hydrate complex); sacubitril (sacubitril valsartan sodium hydrate complex) - tablet - 103mg; 97mg - valsartan (sacubitril valsartan sodium hydrate complex) 103mg; sacubitril (sacubitril valsartan sodium hydrate complex) 97mg - angiotensin ii receptor antagonists

Kenya - English - Pharmacy and Poisons Board

innocia lifesciences pvt ltd innocia lifesciences pvt ltd - sacubitril 49mg and valsartan 51mg tablets - tablet - sacubitril 49mg and valsartan 51mg tablets - valsartan and sacubitril

Kenya - English - Pharmacy and Poisons Board

innocia lifesciences pvt ltd innocia lifesciences pvt ltd - sacubitril 97mg and valsartan 103mg tablets - tablet - sacubitril 97mg and valsartan 103mg tablets - valsartan and sacubitril

Kenya - English - Pharmacy and Poisons Board

innocia lifesciences pvt ltd innocia lifesciences pvt ltd - sacubitril 24mg and valsartan 26mg tablets - tablet - sacubitril 24mg and valsartan 26mg tablets - valsartan and sacubitril

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 50mg (as sodium hydrate complex, contains 24.3 mg sacubitril and 25.7 mg valsartan);  ;   - film coated tablet - 24.3 mg/25.7 mg - active: sacubitril/valsartan 50mg (as sodium hydrate complex, contains 24.3 mg sacubitril and 25.7 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating premix, white basic coating premix, red basic coating premix, black magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 100mg (as sodium hydrate complex, contains 48.6 mg sacubitril and 51.4 mg valsartan);  ;   - film coated tablet - 48.6 mg/51.4 mg - active: sacubitril/valsartan 100mg (as sodium hydrate complex, contains 48.6 mg sacubitril and 51.4 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating premix, white basic coating premix, yellow basic coating premix, red magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 200mg (as sodium hydrate complex, contains 97.2 mg sacubitril and 102.8 mg valsartan);  ;   - film coated tablet - 97.2 mg/102.8 mg - active: sacubitril/valsartan 200mg (as sodium hydrate complex, contains 97.2 mg sacubitril and 102.8 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating mixture, white basic coating mixture, red basic coating mixture, black magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - heart failure - angiotensin ii antagonists, other combinations, agents acting on the renin-angiotensin system - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - heart failure - agents acting on the renin-angiotensin system - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).